These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9737473)

  • 21. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
    Ammollo CT; Semeraro F; Semeraro N; Colucci M
    Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
    [No Abstract]   [Full Text] [Related]  

  • 22. Low molecular weight heparins: differences and similarities in approved preparations in the United States.
    Bick RL; Fareed J
    Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S63-6. PubMed ID: 10726038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin.
    Jeske W; Fareed J; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
    Semin Thromb Hemost; 1997; 23(2):119-28. PubMed ID: 9200335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio.
    Javot L; Lecompte T; Rabiskova M; Maincent P
    J Control Release; 2009 Oct; 139(1):8-14. PubMed ID: 19470393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect on low-molecular-weight heparin obtained using a chitinolytic complex on the anticoagulant activity of plasma in rabbits and rats].
    Drozd NN; Tolstenkov AS; Makarov VA; Miftakhova NT; Bannikova GE; Sukhanova PP; Varlamov VP; Vikhoreva GE
    Eksp Klin Farmakol; 2007; 70(2):40-4. PubMed ID: 17523450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of low-molecular-weight heparins in cardiovascular disease.
    Abbate R; Gori AM; Farsi A; Attanasio M; Pepe G
    Am J Cardiol; 1998 Sep; 82(5B):33L-36L. PubMed ID: 9737479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
    Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
    Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.
    Martínez-González J; Rodríguez C
    Expert Rev Cardiovasc Ther; 2010 May; 8(5):625-34. PubMed ID: 20450295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-molecular-weight heparin.
    Wolf H
    Med Clin North Am; 1994 May; 78(3):733-43. PubMed ID: 8170267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM; Bara L; Gerotziafas GT
    Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.